spacer
home > ebr > summer 2019 > the renaissance of microbial fermentation
PUBLICATIONS
European Biopharmaceutical Review

The Renaissance of Microbial Fermentation

Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Vladas Bumelis is the founder of Northway Biotechpharma and Chairman of the company’s Board of Directors and Advisory Board. He has extensive experience in the pharma and biotechnology industries, having previously served as General Manager of Teva Pharmaceutical Industries, Chairman of the Board for Biofa and Biotechna, and Chairman of the Board and General Manager of the Institute of Applied Enzymology in Lithuania. In 2004, Vladas received the Science Award of Lithuania in recognition of his achievements in the development and production of recombinant proteins. He has a PhD and MSc in chemistry, as well as a PhD in biotechnology, from Vilnius University, Lithuania.
spacer
Dr Vladas Bumelis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers
 
Industry Events

BIO-Europe® 2019 - 25th Annual International Partnering Conference

11-13 November 2019, Hamburg, Germany

The 25th annual BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,350 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business. Learn more.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement